Infiltration of a Unique CD8⁺CD274⁺ Cell Subgroup in Hepatocellular Carcinoma is Associated with Poor Clinical Outcomes

References

• Morse MA, Sun W, Kim R, et al. The role of angiogenesis in hepatocellular carcinoma. Clin Cancer Res. 2019;25(3):912–920. doi:10.1158/1078-0432.CCR-18-1254
   PubMed Web of Science ®Google Scholar
• Zongyi Y, Xiaowu L. Immunotherapy for hepatocellular carcinoma. Cancer Lett. 2020;470:8–17. doi:10.1016/j.canlet.2019.12.002
   PubMed Web of Science ®Google Scholar
• Yi M, Jiao D, Xu H, et al. Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. Mol Cancer. 2018;17(1):129. doi:10.1186/s12943-018-0864-3
   PubMed Web of Science ®Google Scholar
• Sangro B, Chan SL, Meyer T, Reig M, El-Khoueiry A, Galle PR. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. J Hepatol. 2020;72(2):320–341. doi:10.1016/j.jhep.2019.10.021
   PubMed Web of Science ®Google Scholar
• Fakih M, Ouyang C, Wang C, et al. Immune overdrive signature in colorectal tumor subset predicts poor clinical outcome. J Clin Invest. 2019;129(10):4464–4476. doi:10.1172/JCI127046
   PubMed Web of Science ®Google Scholar
• Giraldo NA, Sanchez-Salas R, Peske JD, et al. The clinical role of the TME in solid cancer. Br J Cancer. 2019;120(1):45–53. doi:10.1038/s41416-018-0327-z
   PubMed Web of Science ®Google Scholar
• Pages F, Mlecnik B, Marliot F, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391(10135):2128–2139. doi:10.1016/S0140-6736(18)30789-X
   PubMed Web of Science ®Google Scholar
• Wang J, Li R, Cao Y, et al. Intratumoral CXCR5(+)CD8(+)T associates with favorable clinical outcomes and immunogenic contexture in gastric cancer. Nat Commun. 2021;12(1):3080. doi:10.1038/s41467-021-23356-w
   PubMed Web of Science ®Google Scholar
• Cui K, Yao S, Zhang H, et al. Identification of an immune overdrive high-risk subpopulation with aberrant expression of FOXP3 and CTLA4 in colorectal cancer. Oncogene. 2021;40(11):2130–2145. doi:10.1038/s41388-021-01677-w
   PubMed Web of Science ®Google Scholar
• Liu J, Lichtenberg T, Hoadley KA, et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell. 2018;173(2):400–416 e11. doi:10.1016/j.cell.2018.02.052
   PubMed Web of Science ®Google Scholar
• Satija R, Farrell JA, Gennert D, Schier AF, Regev A. Spatial reconstruction of single-cell gene expression data. Nat Biotechnol. 2015;33(5):495–502. doi:10.1038/nbt.3192
   PubMed Web of Science ®Google Scholar
• Sun D, Guan X, Moran AE, et al. Identifying phenotype-associated subpopulations by integrating bulk and single-cell sequencing data. Nat Biotechnol. 2021. doi:10.1038/s41587-021-01091-3
   Web of Science ®Google Scholar
• Jin S, Guerrero-Juarez CF, Zhang L, et al. Inference and analysis of cell-cell communication using CellChat. Nat Commun. 2021;12(1):1088. doi:10.1038/s41467-021-21246-9
   PubMed Web of Science ®Google Scholar
• Qiu X, Mao Q, Tang Y, et al. Reversed graph embedding resolves complex single-cell trajectories. Nat Methods. 2017;14(10):979–982. doi:10.1038/nmeth.4402
   PubMed Web of Science ®Google Scholar
• Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747–1756. doi:10.1101/gr.239244.118
   PubMed Web of Science ®Google Scholar
• Cui K, Liu C, Li X, Zhang Q, Li Y. Comprehensive characterization of the rRNA metabolism-related genes in human cancer. Oncogene. 2020;39(4):786–800. doi:10.1038/s41388-019-1026-9
   PubMed Web of Science ®Google Scholar
• Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 2013;14:7. doi:10.1186/1471-2105-14-7
   PubMed Web of Science ®Google Scholar
• Yoshihara K, Shahmoradgoli M, Martinez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612. doi:10.1038/ncomms3612
   PubMed Web of Science ®Google Scholar
• Charoentong P, Finotello F, Angelova M, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18(1):248–262. doi:10.1016/j.celrep.2016.12.019
   PubMed Web of Science ®Google Scholar
• Newman AM, Steen CB, Liu CL, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019;37(7):773–782. doi:10.1038/s41587-019-0114-2
   PubMed Web of Science ®Google Scholar
• Li T, Fu J, Zeng Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509–W514. doi:10.1093/nar/gkaa407
   PubMed Web of Science ®Google Scholar
• Ally A, Balasundaram M, Carlsen R; Cancer Genome Atlas Research Network. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell. 2017;169(7):1327–1341 e23. doi:10.1016/j.cell.2017.05.046
   PubMed Web of Science ®Google Scholar
• Thorsson V, Gibbs DL, Brown SD, et al. The immune landscape of cancer. Immunity. 2018;48(4):812–830 e14. doi:10.1016/j.immuni.2018.03.023
   PubMed Web of Science ®Google Scholar
• Bagaev A, Kotlov N, Nomie K, et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell. 2021;39(6):845–865 e7. doi:10.1016/j.ccell.2021.04.014
   PubMed Web of Science ®Google Scholar
• Becht E, Giraldo NA, Lacroix L, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016;17(1):218. doi:10.1186/s13059-016-1070-5
   PubMed Web of Science ®Google Scholar
• Racle J, de Jonge K, Baumgaertner P, Speiser DE, Gfeller D. Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data. Elife. 2017;6. doi:10.7554/eLife.26476
   PubMed Web of Science ®Google Scholar
• Jiang P, Gu S, Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550–1558. doi:10.1038/s41591-018-0136-1
   PubMed Web of Science ®Google Scholar
• Zlobec I, Terracciano L, Jass JR, Lugli A. Value of staining intensity in the interpretation of immunohistochemistry for tumor markers in colorectal cancer. Virchows Arch. 2007;451(4):763–769. doi:10.1007/s00428-007-0466-8
   PubMed Web of Science ®Google Scholar
• Vitale I, Manic G, Coussens LM, Kroemer G, Galluzzi L. Macrophages and metabolism in the tumor microenvironment. Cell Metab. 2019;30(1):36–50. doi:10.1016/j.cmet.2019.06.001
   PubMed Web of Science ®Google Scholar
• Lowery FJ, Krishna S, Yossef R, et al. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. Science. 2022;375(6583):877–884. doi:10.1126/science.abl5447
   PubMed Web of Science ®Google Scholar
• Snell LM, MacLeod BL, Law JC, et al. CD8(+) T cell priming in established chronic viral infection preferentially directs differentiation of memory-like cells for sustained immunity. Immunity. 2018;49(4):678–694 e5. doi:10.1016/j.immuni.2018.08.002
   PubMed Web of Science ®Google Scholar
• Speiser DE, Utzschneider DT, Oberle SG, Munz C, Romero P, Zehn D. T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion? Nat Rev Immunol. 2014;14(11):768–774. doi:10.1038/nri3740
   PubMed Web of Science ®Google Scholar
• Cui K, Yao S, Liu B, et al. A novel high-risk subpopulation identified by CTSL and ZBTB7B in gastric cancer. Br J Cancer. 2022;127(8):1450–1460. doi:10.1038/s41416-022-01936-x
   PubMed Web of Science ®Google Scholar
• Hou J, Zhao R, Xia W, et al. PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis. Nat Cell Biol. 2020;22(10):1264–1275. doi:10.1038/s41556-020-0575-z
   PubMed Web of Science ®Google Scholar
• Zhang R, Li T, Wang W, et al. Indoleamine 2, 3-dioxygenase 1 and CD8 expression profiling revealed an immunological subtype of colon cancer with a poor prognosis. Front Oncol. 2020;10:594098. doi:10.3389/fonc.2020.594098
   PubMed Web of Science ®Google Scholar
• Yu M, Chen Z, Zhou Q, et al. PARG inhibition limits HCC progression and potentiates the efficacy of immune checkpoint therapy. J Hepatol. 2022;77:140–151. doi:10.1016/j.jhep.2022.01.026
   PubMed Web of Science ®Google Scholar
• Cadoux M, Caruso S, Pham S, et al. Expression of NKG2D ligands is downregulated by beta-catenin signalling and associates with HCC aggressiveness. J Hepatol. 2021;74(6):1386–1397. doi:10.1016/j.jhep.2021.01.017
   PubMed Web of Science ®Google Scholar
• Makarova-Rusher OV, Medina-Echeverz J, Duffy AG, Greten TF. The yin and yang of evasion and immune activation in HCC. J Hepatol. 2015;62(6):1420–1429. doi:10.1016/j.jhep.2015.02.038
   PubMed Web of Science ®Google Scholar
• Li L, Lu G, Liu Y, et al. Low infiltration of CD8+ PD-L1+ T cells and M2 macrophages predicts improved clinical outcomes after immune checkpoint inhibitor therapy in non-small cell lung carcinoma. Front Oncol. 2021;11:658690. doi:10.3389/fonc.2021.658690
   PubMed Web of Science ®Google Scholar
• Zgodzinski W, Grywalska E, Zinkiewicz K, et al. Peripheral blood T lymphocytes are downregulated by the PD-1/PD-L1 axis in advanced gastric cancer. Arch Med Sci. 2019;15(3):774–783. doi:10.5114/aoms.2018.75092
   PubMed Web of Science ®Google Scholar
• Hasan Y, Furtado L, Tergas A, et al. A phase 1 trial assessing the safety and tolerability of a therapeutic DNA vaccination against HPV16 and HPV18 E6/E7 oncogenes after chemoradiation for cervical cancer. Int J Radiat Oncol Biol Phys. 2020;107(3):487–498. doi:10.1016/j.ijrobp.2020.02.031
   PubMed Web of Science ®Google Scholar
• Diskin B, Adam S, Cassini MF, et al. PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer. Nat Immunol. 2020;21(4):442–454. doi:10.1038/s41590-020-0620-x
   PubMed Web of Science ®Google Scholar
• Riera-Domingo C, Audige A, Granja S, et al. Immunity, hypoxia, and metabolism-the menage a trois of cancer: implications for immunotherapy. Physiol Rev. 2020;100(1):1–102. doi:10.1152/physrev.00018.2019
   PubMed Web of Science ®Google Scholar
• Batlle E, Massague J. Transforming growth factor-beta signaling in immunity and cancer. Immunity. 2019;50(4):924–940. doi:10.1016/j.immuni.2019.03.024
   PubMed Web of Science ®Google Scholar
• Pfister D, Nunez NG, Pinyol R, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;592(7854):450–456. doi:10.1038/s41586-021-03362-0
   PubMed Web of Science ®Google Scholar
• McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73(Suppl 1):4–13. doi:10.1002/hep.31288
   PubMed Web of Science ®Google Scholar
• Wei Y, Zhao Q, Gao Z, et al. The local immune landscape determines tumor PD-L1 heterogeneity and sensitivity to therapy. J Clin Invest. 2019;129(8):3347–3360. doi:10.1172/JCI127726
   PubMed Web of Science ®Google Scholar
• Sangro B, Sarobe P, Hervas-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(8):525–543. doi:10.1038/s41575-021-00438-0
   PubMed Web of Science ®Google Scholar
• Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500–2501. doi:10.1056/NEJMc1713444
   PubMed Web of Science ®Google Scholar
• Li S, Yu W, Xie F, et al. Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer. Nat Commun. 2023;14(1):8. doi:10.1038/s41467-022-35431-x
   PubMed Web of Science ®Google Scholar